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Protective immunity against several species of malaria parasites has been obtained 
by vaccination with x-irradiated  sporozoites  (reviewed in reference  1). The serum  of 
protected  animals  reacts with  the surface  membrane  of sporozoites  and  neutralizes 
their  infectivity,  which  suggests  that  the  effect  of the  vaccine  is  at  least  in  part 
antibody  mediated.  The  membrane-associated  protective  antigens  of sporozoites  of 
rodent  (2,  3),  simian  (4),  and  human  (5)  malaria  have  recently  been  identified  by 
means  of monoclonal  antibodies  (mAb). 1 They  are  stage-specific  proteins  that  are 
distributed  uniformly over the entire surface of the parasite and are shed when cross- 
linked by antibodies  (3). 
Evidence that these circumsporozoite (CS) proteins of different malaria species are 
structurally,  antigenically,  and  functionally  related  molecules  has  been  presented 
elsewhere  (6).  Of particular  interest  were  the observations  that  Fab  fragments of a 
mAb  against  the  CS  protein  of Plasmodium  berghei  inhibited  the  attachment  and 
interiorization  of these  sporozoites  into  target  ceils  (7).  These  findings  raised  the 
intriguing  possibility that  some of the epitopes  recognized by the mAb might either 
coincide  with  or  be  in  close  proximity  to  the  areas  of the  CS  molecules  that  are 
involved in parasite  penetration. 
To investigate this phenomenon further we compare here the specificities of a series 
of mAb against CS proteins of parasites of monkey (P. knowlesi) and human  (P. vivax 
and  P. falciparum)  malaria,  including  some  that  neutralized  the  infectivity  of the 
sporozoites in vivo (4, 5)  or in vitro.  2 We present  evidence that  in every instance the 
mAb recognize the same unique region of the CS molecule, which contains at  least 
two identical epitopes. 
Materials  and Methods 
Monoclonal Antibodies.  The production and characterization of mAb against sporozoites of P. 
knowlesi, P. falciparum,  and  P.  vivax are  described  elsewhere  (4,  5).  The  mAb were partially 
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purified from ascites fluids by ammonium sulfate precipitation followed by chromatography on 
Sephadex G200. 
Sporozoites.  Sporozoites of P. vivax and P. falciparum  (isolates  from Thailand), as well as P. 
knowlesi  (H strain), were obtained from mosquito salivary glands 14-17 d  after an infective 
blood meal (8). Sporozoite extracts were prepared by placing a known number of sporozoites 
in 500/~l of phosphate-buffered saline containing i% bovine serum albumin (PBS-BSA). Protein 
inhibitors were added as previously described (2). Nonidet P-40 (NP-40)  was then added to a 
final concentration of 0.5%, and the mixtures were incubated at room temperature for  l  h. 
After centrifugation at  I00,000 g for l h, the supernatants were stored at -70°C. 
Antigen-coated Microtiter Plates.  Sporozoites (6 ×  104/ml) were suspended in PBS containing 
protease inhibitors. 50 #1 of this suspension was placed in wells of polyvinylchloride flexible 
microtiter plates (Dynatech Laboratories, Inc., Alexandria, VA). After freezing (-70°C) and 
thawing the plates six times, they were stored at -70°C. Before using, the wells were washed 
three times with PBS-BSA and kept in this solution for 1 h at room temperature. 
Competitive Binding Assays Between Monoclonal Antibodies.  Wells of antigen-coated plates were 
incubated with 30 #1 of cold mAb at a concentration of 50 #g/ml in PBS-BSA.  After 1 h of 
incubation, 10 #1 of one of the 12SI-labeled  mAb (1-10 ng, 104.-  10  s cpm) was added to the wells, 
and the incubation  proceeded for an additional hour. Preliminary  experiments showed that the 
above  concentration of cold  mAb was  25-50  times  greater  than  that  required  to  inhibit 
completely the binding of the hot homologous mAb to the antigen-coated plates. The wells in 
the  plates were  then washed  three  times with  PBS-BSA,  dried, and counted in a  gamma 
counter. This procedure was  repeated  for every possible combination of hot  vs.  cold mAb 
against a  given CS protein. As negative controls, antigen-coated wells were incubated either 
with an unrelated mAb or with PBS-BSA before the addition of the labeled mAb. The number 
of specific  counts bound to antigen in the absence of inhibitor mAb was calculated as the 
difference between the number of counts bound to the wells incubated with the labeled mAb 
in the presence of PBS-BSA and the number of counts that could not be inhibited by an excess 
of the homologous, cold mAb, the latter representing nonspecific binding. From these values 
the percent inhibition of specific binding was calculated for each cold mAb. Results represent 
the means of duplicates. 
Competitive Binding Assays Between mAb and Anti-Sporozoite Immune Sera.  Immune serum anti-P. 
knowlesi  sporozoites  from  rhesus  monkeys was  obtained  by  repeated  immunizations with 
irradiated sporozoites  administered intravenously (9). Human immune sera anti-P, vivax and 
anti-P,  falciparum were obtained from volunteers exposed to multiple bites of irradiated, infected 
mosquitoes and shown to be protected against sporozoite challenge (10, 11). The anti-P, knowlesi 
immune sera were absorbed with salivary glands of uninfected mosquitoes. 100/~1 of immune 
serum diluted  1:10 in PBS-BSA was incubated with  100 packed salivary glands. After 2 h 
incubation at  room  temperature,  the  sample  was  centrifuged  (8,000  g,  5  min)  and  the 
supernatant was used in the assay. 
Anti-sporozoite antibodies were detected by incubating  dilutions of the immune sera in wells 
of microtiter plates coated with homologous antigen. After 2 h incubation at room temperature, 
the wells were washed with PBS-BSA.  Then an excess of affinity-purified, 12~I-labeled IgG of 
rabbit  anti-monkey or  rabbit  anti-human immunoglobulin (Ig)  was  added  to  detect  the 
presence of Ig bound to the immobilized antigen. 
The competitive binding assay between mAb and the immune sera was performed as above, 
except that before the addition of the immune sera, the antigen-coated plates were incubated 
for 1 h with 30/~1 of 10-times-diluted mouse ascites  fluids containing mAb. Every experiment 
included titrations of  (a)  immune sera  after  incubation of the  plates  with  mAb  against 
homologous CS proteins, (b) immune  sera after incubation  with unrelated mAb, and (c) normal 
monkey or human sera after incubation with an unrelated mAb. The counts obtained in group 
c represent background and were subtracted from those obtained in groups a and b. 
Sucrose Gradient Ultracentrifugation.  50/~1  of extract  obtained from 2.5  ×  106 parasites was 
incubated with 50 #1 of a solution containing 2% sodium dodecyl sulfate (SDS) and 6 M urea. ZAVALA ET  AL.  1949 
After  1 h  incubation  at  room  temperature,  10 #g of molecular weight  markers was added 
(mouse IgG, BSA, ovalbumin [OVA], and soybean trypsin inhibitor [STI]). The mixture (0.2 
ml) was placed on the top of a  5-ml tube containing a  linear 5-20% sucrose gradient in PBS. 
The runs were performed in a  Beckman  L8-80 ultracentrifuge  (Beckman Instruments,  Inc., 
Fullerton, CA) with a  SW-50.1 rotor (DuPont Instruments-Sorvall Biomedical Div., DuPont 
Co., Wilmington, DE) at 48,000 rpm for 15 h. Fractions of- 125/~1 were collected by perforating 
the bottom  of the tube.  Aliquots of each  fraction were subject to  SDS-polyacrylamide gel 
electrophoresis. The gels were dried and stained to determine the position of the markers. Each 
fraction was tested for the presence of antigen by the two assays described below. One of these 
(the inhibition assay) detects antigen molecules bearing single epitopes and the other (the two- 
site assay) detects only muhivalent antigens. 
Inhibition Assay to Detect the Presence of Antigen in Fractions of Sucrose Gradient.  10/L1 (5 ×  104 
epm,  1-5 ng) of radiolabeled mAb (2G3 anti-CS protein of P. knowlesi or 2F2 anti-CS protein 
of P. vivax) was incubated with 30/~1 of each fraction from the sucrose gradient. After 1 h  at 
room temperature, 30 #1 of each mixture was added to an antigen-coated plate, incubated for 
1 h, washed, and counted. The results were expressed as the number of sporozoites present in 
each fraction as calculated from a standard curve obtained simultaneously with each assay. 
Two-Site~One-Antibody Imrnunoradiometric Assay.  Wells of a  microtiter plate were incubated 
overnight at 4°C with 50 #1 of a  10/~g/ml solution of purified mAb in PBS. The wells were 
washed and incubated for 60 min with PBS-BSA. 35/~1 of dilutions of sporozoite extracts was 
added to separate wells and the plates were incubated at room temperature for 4 h. The wells 
were washed with PBS-BSA and 30/~1 (1 X  10  ~ cpm, 5-10 ng) of 125I-labeled mAb (the same 
used to coat the wells) was added to each well. After 1 h of incubation at room temperature, 
the wells were washed, dried, and counted. The number of counts bound to control wells that 
had been coated with an  unrelated mAb or with PBS-BSA before addition of extracts was 
negligible. 
When fractions of the sucrose gradient were tested for the presence of antigen, 35/~1 of each 
fraction was added to the antibody-coated wells. The  assay proceeded in the same way as 
described above. The results were expressed as the number of sporozoites contained in each 
fraction, as calculated from a standard curve obtained on the same day of the experiment. 
Radiolabeling ofmAb.  25 gtl (25/xg) of purified mAb was radiolabeled with  1-2 mCi of 12~I, 
using Iodogen (Pierce Chemical Co., Rockford, IL) and the method suggested by the manufac- 
turers. The  free 125I was  removed by passage of the sample through  Sephadex G-25 PD-10 
columns (Pharmacia Fine Chemicals, Piscataway, N  J), followed by extensive dialysis against 
PBS.  Specific activities of the  radiolabeled mAb  ranged  between  2  and  3  ×  107  cpm  per 
microgram of protein. 
Results 
Topological Analysis of Antigenic Determinants on CS Proteins.  Panels of mAb were used 
to study the arrangement  of the epitopes of CS proteins within single molecules by 
using a  competition binding assay (12-14).  These were performed with five mAb to 
P. vivax derived from three different fusions, five mAb to P.falciparum  from two fusions, 
and six mAb to P. knowlesi  from a  single fusion. Results are expressed as percentage 
inhibition  of binding  of each  mAb  by  the  others  and  calculated  as  described  in 
Materials and Methods. As seen in Table I, all mAb to P. vivax, P. falciparum,  and P. 
knowlesi  inhibited  the  binding  of each  other  to  the  homologous  CS  antigen.  This 
inhibition was specific, because unrelated mAb had no activity. In some cases there 
was incomplete inhibition. For example, the binding of x25I-2F2 anti-P, vivax was only 
partially inhibited in the presence of an excess of the other antibodies. However, an 
excess of cold 2F2  in  the  incubation  medium  inhibited  100%  of the binding of all 
radiolabeled antibodies.  Similarly, an  excess of 8Ell  inhibited only 60-80%  of the 1950  IMMUNODOMINANT REGION OF CIRCUMSPOROZOITE PROTEINS 
TABLE  I 
Evidence  for the Presence of an Immunodominant Region on CS Proteins 
Cold inhibitor  Percent inhibition of binding to antigen 
(mAb)  of the radiolabeled mAb 
P. vivax  3D10  5D9  3C1  4E8  2F2 
3D 10  100  102  99  101  59 
5  D9  83  100  98  101  65 
3C1  113  103  100  102  67 
4E8  105  100  99  100  60 
2F2  100  101  100  116  100 
Control mAb  8  --6  -  11  3  6 
PBS-BSA  0  0  0  0  0 
P. knowlesi  5H8  2G3  8B8  8A8  8E 11  6B8 
5H8  I00  99  101  115  105  12I 
2G3  96  100  87  78  106  103 
8B8  95  94  100  I06  107  125 
8A8  86  83  94  1  DO  105  128 
8E 11  65  59  86  70  100  105 
6B8  88  85  91  95  104  100 
Control mAb  6  0.4  0,5  8  0  0 
PBS-BSA  0  0  0  0  0  0 
P. falciparum  3D6  2  E 7  1  E9  2C 11  2A 10 
3D6  100  98  99  95  75 
2E7  98  100  102  99  90 
1E9  100  103  100  100  99 
2C 11  104  100  99  100  100 
2At0  110  102  106  i00  I00 
Control rnAb  2  0  -4  8  0 
PBS-BSA  0  0  0  0  0 
binding  of several antibodies  to P.  knowlesi,  but  all antibodies  inhibited  100%  of the 
binding  of radiolabeled  8El I  to  the  antigen.  Identical  results  were  obtained  when 
four anti-P,  berghei  mAb  were subjected to this analysis  (not  shown). 
Competitive  Assay  Between  mAb  and  Anti-Sporozoite  Immune  Sera.  The  experiments 
described below were performed  to determine whether polyclonal human  antibodies 
to  sporozoites  of P. falciparum  and  P.  vivax,  and  monkey  antibodies  to  P.  knowlesi 
recognize the same region of the CS molecule as that  seen  by the homologous  mAb. 
The immune  sera were obtained from humans  or monkeys vaccinated with irradiated 
sporozoites  and  shown  to  be  fully protected  when  challenged  with  viable  parasites. 
Wells  of plates  coated  with  crude  extracts  of sporozoites  were  first  incubated  with 
ascites fluids containing mAb  to CS proteins. Then  immune  sera at different dilutions 
were added  to the wells. The  presence of polyclonal antibody  bound  to the immobi- 
lized antigen was demonstrated by the specific binding of 125I-labeled, affinity-purified 
rabbit  anti-monkey  or  rabbit  anti-human  Ig.  As  shown  in  Fig.  1,  all  polyclonal 
antisera  contained  antibodies  that  bound  to  the solid-phase-associated  antigen,  and 
in each case a  single mAb inhibited  70-95% of the binding of the polyclonal antibodies 
to  the  wells.  It  appears,  therefore,  that  in  the  vaccinated  and  protected  hosts,  most ZAVALA ET  AL.  1951 
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Fzc.  1.  Inhibitory effect  of mAb to  CS  proteins  on  the  binding of polyclonal  antibodies to 
sporozoite extracts. The experiments represented  above were performed in two steps. First, serial 
dilutions of polyclonal antisera were incubated with a crude extract of sporozoites in the presence 
or absence of a mAb. Then the amounts of polyclonal Ig that bound to the solid-phase-associated 
antigen were measured using an excess of radiolabeled, affinity-purified anti-Ig of the appropriate 
specificity. As shown, the mAb inhibited 70-95% of the binding of the polyclonal antibody to 
antigen. 
circulating antibodies are directed against CS proteins, and that the mAb and most 
of the polyclonal antibodies recognize the same epitope. 
Demonstration  That  the  CS Proteins  Contain  Two or More  Identical  Epitopes.  This  was 
shown using a two-site immunoradiometric assay. In this type of assay the concentra- 
tion of antigen is usually measured by means of two antibodies of different specificities. 
The  first  antibody, bound  to  a  solid support,  serves to  isolate and  concentrate  the 
antigen. The concentration of bound antigen is then obtained by adding an excess of 
a  second  labeled  antibody  directed  against  the  same  antigen  but  recognizing  a 
different epitope. In the experiments shown in Fig. 2 we performed two-site assays to 
detect and  measure CS proteins in extracts of parasites, but  we used  a  single mAb 
both in the solid phase and as a  radiolabeled developing reagent. We reasoned that 
use of a  single mAb would be equally effective if the antigen contained two identical 
and  topographically separated epitopes. We  performed  antigen  titrations with  this 
two-site/one-antibody assay using extracts of several species ofsporozoites. The results 1952  IMMUNODOMINANT  REGION OF CIRCUMSPOROZOITE  PROTEINS 
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Fio.  2.  Two-site/one-antibody imrnunoradiometric assays for detection of sporozoites. Sporozoite 
extracts were incubated in wells of microtiter plates coated with a mAb to a CS protein. After 
washing, the amount of antigen bound to the solid phase was measured by adding to the wells an 
excess of the same mAb radiolabeled with ]~I. 
showed  that  this  assay not  only detected  the  antigen  specifically, but  also that  its 
sensitivity was identical to that of the two-site/two-antibody assay described elsewhere 
(15);  that is, positive results were obtained when extracts contained between 5 X  l0  s 
and  104 sporozoites/ml.  Identical results to those of Fig.  2 were obtained when  the 
diluent used in the two-site/one-antibody assay contained 0.5% NP-40. 
To determine the molecular weights of the CS proteins that contain the repeated 
epitopes, solubilized sporozoites were obtained as described in Materials and Methods 
and  then  mixed with  equal  volumes of 2%  SDS  and  6  M  urea.  The  mixture was 
overlaid onto a preformed sucrose gradient and subjected to ultracentrifugation. The 
presence of CS proteins in gradient fractions was determined by means of two different 
assays; that is, by the two-site/one-antibody immunoradiometric assay, which depends 
on the multivalency of the antigen, and by the inhibition of binding of radiolabeled 
antibody to antigen-coated plates, which can detect monovalent antigens. To facilitate 
comparison of the  results of the  two assays, the  amounts of antigen  detected  were 
expressed in sporozoite equivalents, as calculated from standard curves performed on 
the same day as the experiment. 
As seen in Figs. 3A and 4A, the CS protein ofP. vivax and P. knowlesi was detected 
with the two-site assay in a  single peak between BSA and OVA. This position is the 
expected  one  for monomers of the CS  proteins  (and  their  intracellular  precursors) @ 
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Fro.  3.  Detection of CS protein in P. oivax  extracts subjected to sucrose gradient ultracentrifugation. 
Extracts of P. vivax in 3 M  urea and 1% SDS were subjected to uhracentfifugation in linear 5-20% 
sucrose gradients. Fractions from the gradient were analyzed by two assays.  (A) The two-site/one- 
antibody  immunoradiometric assays detect  bivalent or  polyvalent antigens.  These  assays were 
performed with different mAb (2F2, Zk; 5D9, O; 3Ct, e) with identical results. (B) The inhibitory 
activity of fluid-phase antigen on the binding of a radiolabeled mAb (2F2) to solid-phase-associated 
antigen was measured. This assay can detect monovalent antigen. Both assays detected antigen 
sedimenting as a single peak between the OVA and BSA markers. 
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Fro.  4.  Detection of P.  knowlesi CS  protein  in  parasite extracts  subjected to  sucrose gradient 
uhracentrifugation. Extracts of P. knowlesi were analyzed exactly as described in the legend of Fig. 
3. Assays were performed with 2G3 (A), 5H8 (O), and 8El 1 (0). The CS protein sedimented as a 
single peak between the OVA and BSA markers. 
that  have  molecular  weights between  40,000  and  60,000  (6).  We  calculated  that  the 
antigen  recovered  in  this  peak  represented  >90%  of the  amount  loaded  onto  the 
gradient. Similar results were obtained  when the fractions were tested by the inhibition 1954  IMMUNODOMINANT REGION  OF  CIRCUMSPOROZOITE PROTEINS 
assay (Figs.  3 B and 4 B). 
Identical results were obtained when CS proteins from P. falciparum  were subjected 
to  this  analysis  (not  shown).  It  should  be  pointed  out  that  two-site/one-antibody 
immunoradiometric assays of gradient fractions were performed simultaneously with 
several  individual  mAb.  As  also  shown  in  Figs.  3A  and  4A,  the antigenic profiles 
obtained  with  all  homologous mAb  were superimposable.  These findings  strongly 
suggest that each monomer is multivalent with respect to epitope expression. 
Discussion 
The purpose of the experiments described in this paper was to study the number of 
independent  antigenic  sites  of CS  proteins.  Our  initial  approach  was  to  use  a 
competitive binding assay to determine the number of  nonoverlapping sites recognized 
by a  panel of mAb. The underlying principle of this assay is that  the binding of a 
radiolabeled antibody to an antigen will be prevented only by other antibodies that 
recognize the same, or topographically related, sites.  Of course, this assumption will 
be considerably strengthened if the inhibitory effects of the ligands are reciprocal (12- 
14).  As shown  in Table I, all  mAb  to CS proteins of P. falciparum,  P.  vivax,  and P. 
knowlesi  interacted competitively with the respective antigens. The inhibitory effects 
were quite strong, ranging from 60 to  100%. In a  few instances the competition was 
asymmetrical. This is probably a  reflection of the difference in avidity between the 
antibodies, because in these reactions, the ligand with higher avidity will be favored. 
Similar effects have been previously described in other systems (12). 
The simplest interpretation of these results is that all mAb to CS proteins recognize 
a single region of the protein, which is immunodominant. This hypothesis is supported 
by the experiments shown in Fig.  1, which demonstrate that single mAb to the CS 
protein of P.  vivax,  P. falciparum,  or P.  knowlesi  inhibited  70-95%  of the binding  of 
polyclonal antibodies  to the respective antigens.  It should be pointed out  that  the 
polyclonal antisera had been prepared by vaccination of humans and monkeys with 
irradiated intact sporozoites and that the assays were performed with crude extracts 
of sporozoites as a source of antigen. Therefore, it appears that not only are the CS 
proteins the most immunogenic constituents of sporozoites, but also that the epitope 
recognized  by  the  immune  system  of monkeys  and  humans  is  identical  to  that 
recognized by the mAb. 
The detection in CS proteins, whose molecular weights vary between 40,000 and 
60,000, of a single immunoreactive area, was unexpected. For example, molecules as 
small  as myogtobin (16,900 mol wt)  have five different immunoreactive areas and 
bind four antibody molecules simultaneously (16). Also, using the competitive binding 
assay,  two epitopes  have  been  found on  both envelope proteins of leukemia  virus 
(70,000 and  15,000  tool wt)  (12). 
The explanation for the high immunogenicity of a single region of the CS proteins 
is  not  known.  The finding that  these molecules contain recurrent epitopes may be 
relevant because the multiplicity within CS proteins of possible recognition sites by 
cells of the immune system could increase their antigenicity. The presence of several 
identical or similar epitopes within CS proteins was demonstrated by their ability to 
bind simultaneously two or more molecules of the same mAb (Fig. 2). To exclude the ZAVALA ET AL.  1955 
possibility that the apparent multivalence is artifactual and a consequence of aggre- 
gation of the antigen, parasite extracts were treated with SDS-urea and subjected to 
ultracentrifugation in sucrose gradients. Analysis of gradient fractions by two methods 
showed that a  multivalent antigen sedimented between BSA and OVA, as expected 
for monomers of CS proteins (Figs. 3 and 4). 
Another important  observation was  that  every mAb  tested detected a  recurrent 
epitope (Figs. 3 A and 4 A). This finding strongly suggests that all antibodies recognize 
a  unique  structure  of the  molecules  present  in  the  immunodominant  region.  In 
agreement with these observations, a cDNA clone from the CS protein of P. knowlesi 
has been recently isolated, and the sequence encoded by this clone was expressed in 
a fl-lactamase fusion protein of the plasmid pBR322. The fusion protein was detected 
by the two-site/one-antibody assay. Preliminary DNA sequencing data indicate that 
the expressed fragment of CS protein contains multiple repeats of a sequence of amino 
acids that react with the mAb (17). 
Whatever the reason for the unique immunologic properties of CS  proteins, the 
present findings, taken together with previous observations, have implications for the 
development of a  malaria vaccine. In the first place, it is clear that CS protein are 
potent  immunogens.  Every mAb  produced  to  date  in  our  laboratory  against  the 
surface membrane of sporozoites has been shown to be directed against a CS protein. 
Also, the sera of volunteers vaccinated with sporozoites of P. vivax or P. falciparum (this 
paper and reference 5), or the serum of adults living in endemic areas  (18), contain 
antibodies to CS proteins. 
Perhaps of even greater significance is the demonstration that  a  single recurrent 
epitope appears to contain most of the immunogenic activity of CS proteins. Because 
the binding of Fab fragments of mAb to this structure neutralizes the infectivity of 
sporozoites, it is possible that a small portion of the CS molecule represented in this 
epitope could be used to produce protective immunity in the host. 
Summary 
We have used panels of monoclonal antibodies to circumsporozoite (CS) proteins 
of Plasmodium falcipariurn,  P.  vivax, and  P.  knowlesi  to  determine  the  number  of 
topographically independent  epitopes of these antigens.  The results of competition 
binding assays indicated that single regions of the CS molecules were recognized by 
the homologous monoclonal antibodies. Competition binding assays were also used to 
study the specificity of antibodies contained in the sera of humans and monkeys that 
had developed sterile immunity after immunization with irradiated, intact sporozoites. 
We found that single monoclonal antibodies inhibited 70-95% of the specifiC binding 
of the polyclonal antibodies to crude extracts of sporozoites. It appears, therefore, that 
CS proteins are among the most immunogenic constituents of sporozoites, and that a 
single region of these molecules contains most of the immunogenic activity. 
An  additional  finding was  that  the immunodominant  region of CS  molecules is 
multivalent with regard to the expression of a single epitope. This was demonstrated 
by  the  ability  of monomers  of CS  proteins  to  bind  simultaneously  two  or  more 
molecules of the same monoclonal antibody. 
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